Abrocitinib and Pazopanib interaction
Abrocitinib and Pazopanib: the Pazopanib prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Pazopanib (VOTRIENT) label · effective 2025-12-16
Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP.
Transporters Coadministration of strong inhibitors of P-gp or BCRP may increase pazopanib concentrations.
Consider selection of alternative concomitant medicinal products with no or minimal potential to inhibit P-gp or BCRP.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.